Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial
MT newswire2026/09/22 12:50Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
US LNG exports surged to the second-highest level in history in October, with Europe accounting for 60% of demand
In October, U.S. LNG exports reached 7.92 million metric tons, only slightly below the record high of 8.01 million metric tons set in April this year, and saw a significant month-on-month increase from 7.12 million metric tons in September. Europe continues to expand its purchases of U.S. LNG, with its share surging 8 percentage points from the previous month to 60%. Analysts point out that Europe's underground gas storage facilities are nearly full; if temperatures in the Northern Hemisphere remain normal this winter, high global inventories may put downward pressure on prices.
BUZZ-Vertex Pharmaceuticals shares rise after raising 2026 revenue forecast
Tenuis: Apple achieves growth in most markets in the fourth fiscal quarter
Palantir's Q3 revenue doubles, U.S. commercial income surpasses government income for the first time, full-year guidance significantly raised | Earnings Report Insights
Palantir’s Q3 revenue reached $2.313 billion, marking a 96% year-on-year increase and surpassing the market expectation of $2.18 billion. U.S. commercial revenue stood at $984 million, soaring 148% year-on-year and exceeding the expected $937 million. For the first time, it surpassed U.S. government revenue, which was $953 million. Adjusted earnings per share were $0.44, higher than the estimated $0.41. The company raised its full-year revenue forecast to between $8.53 billion and $8.534 billion, above the market consensus of $8.2 billion.
Crypto prices
More
